Arbutus' imdusiran with short course interferon achieves sustained undetectable hbsag, a necessity for hbv functional cure

At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (ifn) for 24 weeks and ongoing nucleoside analogue (na) therapy achieved undetectable levels of hbsag that were maintained in 100% of these patients 24 weeks after completing imdusiran and ifn treatment
ABUS Ratings Summary
ABUS Quant Ranking